<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2383">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05130138</url>
  </required_header>
  <id_info>
    <org_study_id>2021-0401</org_study_id>
    <secondary_id>2021-A00942-39</secondary_id>
    <nct_id>NCT05130138</nct_id>
  </id_info>
  <brief_title>Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia</brief_title>
  <acronym>PHARM-LMC</acronym>
  <official_title>Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia: PHARM-LMC Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Cancérologie de la Loire</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de Cancérologie de la Loire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this trial is therefore to identify concomitant treatments with taking Tyrosine&#xD;
      Kinase Inhibitor (=TKI) in the indication of Chronic Myeloid Leukemia (CML), whatever the&#xD;
      stage of the disease, via pharmaceutical conciliation. These concomitant treatments as well&#xD;
      as their dosages will be correlated with the TKI dosage since patients must have a sufficient&#xD;
      residual concentration to be considered effective and to confirm adherence to treatment, the&#xD;
      leading cause of treatment failure.&#xD;
&#xD;
      In the event of unsatisfactory results, pharmaceutical interventions may take place: changes&#xD;
      in treatments (TKI and not TKI) and / or dosages. In case of modification, a new dosage of&#xD;
      TKI should be carried out.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic myeloid leukemia (CML) is a clonal myeloproliferative syndrome with an estimated&#xD;
      incidence of 0.8-1 cases per 100,000 person-years in 2018 in France. CML is characterized by&#xD;
      the transformation of a pluripotent stem cell resulting in an increase in myeloid and&#xD;
      erythroid lineages and megakaryocytes in peripheral blood as well as myeloid hyperplasia in&#xD;
      the bone marrow.&#xD;
&#xD;
      In the absence of treatment, the disease, which begins in a chronic phase over a few years,&#xD;
      progresses to an acceleration phase, before reaching an acute phase, known as a blast crisis,&#xD;
      with a poor prognosis. This abnormal proliferation of white blood cells results from the&#xD;
      reciprocal translocation (exchange) between chromosomes 9 and 22. This exchange brings two&#xD;
      normally distinct genes into contact: the (breakpoint cluster region) BCR gene and the abl&#xD;
      gene (Tyrosine-protein kinase), which will form an abnormal gene called &quot;fusion Bcr-abl&quot;.&#xD;
      This gene encodes a fusion protein with deregulated tyrosine kinase activity that activates&#xD;
      various mechanisms involved in cell multiplication.&#xD;
&#xD;
      Since the 1990s, the arrival of the first tyrosine kinase inhibitor (TKI), imatinib, has&#xD;
      radically changed patient management. Indeed, according to Public Health France, this&#xD;
      treatment has allowed the majority of patients to remain in the chronic phase for a long&#xD;
      time. Patient survival has therefore increased dramatically as the life expectancy of&#xD;
      patients with CML taking their treatment regularly approaches that of the general population.&#xD;
&#xD;
      However, even though several generations of TKI have been developed, certain toxicities may&#xD;
      lead to discontinuation of treatment, or to a modification of the dose. Indeed, a&#xD;
      meta-analysis published in June 2020 shows that second and third generation of TKI improve&#xD;
      the major molecular response by 3 months, but are associated with a recrudescence of&#xD;
      thrombocytopenia, cardiovascular, pancreatic and hepatic events. First generation imatinib&#xD;
      therefore remains the best option for patients with co-morbidities despite the frequent&#xD;
      presence of headaches, digestive disorders, and cramps.&#xD;
&#xD;
      It has therefore always been customary to change the TKI or modify the prescribed doses,&#xD;
      while the side effects or ineffectiveness of these inhibitors could be explained by drug&#xD;
      interactions, or be related to the use of herbal medicine. Indeed, TKIs are metabolized by&#xD;
      the cytochrome P450 system. The activity of this cytochrome is not only different from one&#xD;
      person to another, but can also be affected by other treatments. For example, some treatments&#xD;
      will inhibit the activity of this cytochrome P450, increasing the exposure of TKIs in plasma.&#xD;
      The pharmacokinetics of the drug will therefore depend on these concomitant treatments and&#xD;
      their influence, among others, on cytochrome P450.&#xD;
&#xD;
      In addition, the median age at diagnosis is respectively 61 years for men and 62 years for&#xD;
      women. These patients are therefore often carriers of other chronic diseases and are have&#xD;
      multiple treatments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients for whom pharmaceutical interventions have been done</measure>
    <time_frame>12 months</time_frame>
    <description>Number of patients for whom pharmaceutical interventions have been done secondly to pharmaceutical conciliation will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Molecular response</measure>
    <time_frame>12 months</time_frame>
    <description>Molecular response will be reported via BCR-ABL transcript rate measured by quantitative polymerase chain reaction (qPCR) or digital polymerase chain reaction (PCR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concomitant treatments</measure>
    <time_frame>12 months</time_frame>
    <description>Concomitant treatments will be reported during 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tyrosine kinase inhibitor observance</measure>
    <time_frame>12 months</time_frame>
    <description>Observance to Tyrosine kinase inhibitor will be measured with Girerd Questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>12 months</time_frame>
    <description>Number and description of sides effects will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' satisfaction</measure>
    <time_frame>12 months</time_frame>
    <description>Patients' satisfaction will be measured with a visual scale from 0 to 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>Patients' quality of life will be measured with the Quality of Life questionnaires (QLQ-C30) questionnaire. The maximum score is 126, the minimum score is 30. More the score is, worst the health state is.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Pharmaceutical conciliation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with Chronic Myeloid Leukemia taking TKI with a molecular response &lt; 4,5 Log will participate to pharmaceutical conciliation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmaceutical intervention</intervention_name>
    <description>Patients with pharmacokinetic and/or pharmacodynamics interactions will be proposed to participate to educational sessions to discuss about treatments taken and modifications possibilities.</description>
    <arm_group_label>Pharmaceutical conciliation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Major patient;&#xD;
&#xD;
          -  Patient affiliated to a social security scheme;&#xD;
&#xD;
          -  Patient suffering from Chronic Myeloid Leukemia, taking a Tyrosine Kinase Inhibitor&#xD;
             (Imatinib, Nilotinib, Dasatinib, or Bosutinib);&#xD;
&#xD;
          -  Molecular response &lt; 4,5 Log;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Legal incapacity or limited capacity ; Medical or psychological incapacity or limited&#xD;
             capacity;&#xD;
&#xD;
          -  Not able to read and/or to write French;&#xD;
&#xD;
          -  Patient taking Ponatinib.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandrine Menguy, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie Lucien Neuwirth</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandrine Menguy, MD, PhD</last_name>
    <phone>0477917136</phone>
    <phone_ext>+33</phone_ext>
    <email>sandrine.menguy@icloire.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mathilde Maison, MsC</last_name>
    <phone>0477917136</phone>
    <phone_ext>+33</phone_ext>
    <email>mathilde.maison@icloire.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Sandrine Menguy, MD, PhD</last_name>
      <phone>0477917136</phone>
      <phone_ext>+33</phone_ext>
      <email>sandrine.menguy@icloire.fr</email>
    </contact>
    <contact_backup>
      <last_name>Mathilde Maison, MsC</last_name>
      <phone>0477917136</phone>
      <phone_ext>+33</phone_ext>
      <email>mathilde.maison@icloire.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Denis GUYOTAT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karine AUGEUL MEUNIER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Silvia Maria BEZSERA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emilie CHALAYER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe COLLET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jérôme CORNILLON</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ludovic FOUILLET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fressia HONEYMAN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline LEJEUNE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thierry MURON</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gilbert SOGLU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuelle TAVERNIER TARDY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pauline DOUCEY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabien FORGES</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie KALFON</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Agnès MACE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 13, 2021</study_first_submitted>
  <study_first_submitted_qc>November 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hematology</keyword>
  <keyword>Chronic Myeloid Leukemia</keyword>
  <keyword>Tyrosine Kinase Inhibitor</keyword>
  <keyword>pharmaceutical conciliation</keyword>
  <keyword>pharmaceutical intervention</keyword>
  <keyword>drug interactions</keyword>
  <keyword>phytotherapy</keyword>
  <keyword>targeted therapies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

